Alrestatin, a lens aldose reductase inhibitor, decreased i.v. arginine-induced glucagon
levels and augmented arginine-stimulated insulin release in the ether anesthetized
rat. Alrestatin may then be useful in the treatment of diabetes mellitus, due to its
actions on insulin and glucagon, and its capacity to delay the onset of sugar-induced
cataracts in the rat.
Alrestatin - Lens Aldose Reductase - Inhibition of Arginine-induced Glucagon Release
- Augmentation of Arginine-Induced Insulin Release - Diabetes
